Homocysteine as a predictor of cognitive decline in Alzheimer's disease.

Homocysteine as a predictor of cognitive decline in Alzheimer's disease.

Show other versions (1)

OBJECTIVE: Moderately elevated levels of plasma total homocysteine are associated with an increased risk of developing Alzheimer's disease. We have tested whether baseline concentrations of homocysteine relate to the subsequent rate of cognitive decline in patients with established Alzheimer&#...

Full description

Bibliographic Details
Main Authors:	Oulhaj, A, Refsum, H, Beaumont, H, Williams, J, King, E, Jacoby, R, Smith, A
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Homocysteine as a predictor of cognitive decline in Alzheimer's disease
by: Oulhaj, A, et al.
Published: (2010)

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.
by: de Jager, C, et al.
Published: (2012)

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial
by: De Jager, C, et al.
Published: (2012)

Homocysteine, B vitamins, and cognitive impairment
by: Smith, A, et al.
Published: (2016)

Homocysteine – A predictor for five year-mortality in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia
by: Ines Elisabeth Futschek, et al.
Published: (2023-02-01)

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial
by: Smith, A, et al.
Published: (2010)

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
by: Smith, A, et al.
Published: (2010)

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
by: Smith, A, et al.
Published: (2010)

Homocysteine, B vitamins, and cardiovascular disease.
by: Refsum, H, et al.
Published: (2006)

Homocysteine, B vitamins, and cardiovascular disease
by: Refsum, H, et al.
Published: (2006)

APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
by: Martins, C, et al.
Published: (2005)

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial
by: De Jager, C, et al.
Published: (2012)

Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment
by: Oulhaj, A, et al.
Published: (2016)

Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.
by: Clarke, R, et al.
Published: (1998)

Elevated homocysteine and N-methyl-d-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome.
by: Jones, S, et al.
Published: (2017)

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
by: A David Smith, et al.
Published: (2010-09-01)

PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer's disease patients.
by: Belbin, O, et al.
Published: (2009)

Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study.
by: Nurk, E, et al.
Published: (2005)

The hordaland homocysteine study: A community-based study of homocysteine, its determinants, and associations with disease
by: Refsum, H, et al.
Published: (2006)

Anti‐N‐homocysteine‐protein autoantibodies are associated with impaired cognition
by: Olga Włoczkowska, et al.
Published: (2021-01-01)

Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease.
by: Belbin, O, et al.
Published: (2007)

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment.
by: Douaud, G, et al.
Published: (2013)

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment
by: Douaud, G, et al.
Published: (2013)

Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.
by: Combrinck, M, et al.
Published: (2006)

Constructional apraxia in Alzheimer's disease: association with occipital lobe pathology and accelerated cognitive decline.
by: Smith, M, et al.
Published: (2001)

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
by: Holmes, C, et al.
Published: (2005)

Facts and recommendations about total homocysteine determinations: an expert opinion
by: Refsum, H, et al.
Published: (2004)

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
by: Ballard, C, et al.
Published: (2005)

The effects of cell cycle progression and Alzheimer-type pathology on cognitive decline
by: Smith, M, et al.
Published: (2000)

Cognitive declines precede and predict functional declines in aging and Alzheimer's disease.
by: Laura B Zahodne, et al.
Published: (2013-01-01)

Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study.
by: Halsted, C, et al.
Published: (2007)

316 Frontal-cerebellar EEG source localization and functional connectivity as predictors of Alzheimer’s disease-related cognitive decline
by: Elizabeth R. Paitel, et al.
Published: (2022-04-01)

Homocysteine and dementia – an international consensus statement
by: Smith, DA, et al.
Published: (2018)

Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease.
by: Lai, M, et al.
Published: (2002)

Low vitamin B-12 status in confirmed Alzheimer's disease as revealed by serum holotranscobalamin.
by: Refsum, H, et al.
Published: (2003)

Repurposing verapamil for prevention of cognitive decline in sporadic Alzheimer’s disease
by: Heba A Ahmed, et al.
Published: (2022-01-01)

Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease
by: Allen, G, et al.
Published: (2016)

Impact of atrial fibrillation on the cognitive decline in Alzheimer’s disease
by: Taizen Nakase, et al.
Published: (2023-01-01)

Comprehensive Review of Nutraceuticals against Cognitive Decline Associated with Alzheimer’s Disease
by: Edwin E. Reza-Zaldívar, et al.
Published: (2023-09-01)

Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels.
by: Tunbridge, E, et al.
Published: (2008)